Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs

01.11.2003 | Original Research Article

Central Components of the Analgesic/ Antihyperalgesic Effect of Nimesulide: Studies in Animal Models of Pain and Hyperalgesia

verfasst von: Dr Cristina Tassorelli, Rosaria Greco, Giorgio Sandrini, Giuseppe Nappi

Erschienen in: Drugs | Sonderheft 1/2003

Einloggen, um Zugang zu erhalten

Abstract

The analgesic action of NSAIDs has been attributed to the peripheral inhibition of prostaglandin synthesis via the blockade of the enzyme cyclo-oxygenase (COX) and prevention of bradykinin and cytokine-induced hyperalgesia via inhibition of the release of tumour necrosis factor-α. However, it is becoming increasingly evident that NSAIDs exert their analgesic effect through several mechanisms. Recent data suggest that significant expression of COX-2 is found in the central nervous system, where COX-2 seems to have, together with nitric oxide, an important role in spinal nociceptive transmission. Nitroglycerin is a nitric oxide donor and induces a hyperalgesic state, partially mediated by central mechanisms. Nimesulide is a preferential COX-2 inhibitor widely used to treat pain.
In this study, we evaluated the analgesic effect of nimesulide in several animal models of pain, intending to provide additional information on the characteristics of the analgesic effect of nimesulide, with specific focus on a possible central component.
Study Design: Nimesulide was compared with vehicle in groups of 4–10 rats that were randomly tested with different models of pain. The experimental design also included study of the effect of nimesulide upon nitroglycerin-induced neuronal activation at central sites. Analysis of variance was used to evaluate the influence of time and treatments. Differences between groups at specific time-points were analysed by post-hoc t-test. A probability level of less than 5% was regarded as significant.
Methods: The analgesic effect of nimesulide (or vehicle) was evaluated in male Sprague-Dawley rats. The animals underwent tail-flick and formalin tests, both performed in baseline conditions and after nitroglycerin-induced hyperalgesia. Two separate groups of rats were treated with nitroglycerin alone or nimesulide followed by nitroglycerin, and their brains were processed for immunocytochemical detection of Fos protein, a marker of neuronal activation.
Results: Nimesulide showed a significant analgesic effect in both the tail-flick and the formalin tests in baseline conditions. In addition, the drug proved effective in counteracting nitroglycerin-induced hyperalgesia in both tests. Brain mapping of nuclei activated by the administration of nitroglycerin showed that nimesulide pretreatment significantly inhibited neuronal activation in several areas, namely the supraoptic nucleus, ventrolateral column of the periaqueductal grey, locus coeruleus, nucleus tractus solitarius and area postrema.
We conclude that nimesulide possesses a strong analgesic and antihyperalgesic activity, the mechanisms of action of which are partly central.
Literatur
1.
Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232–5PubMed
2.
Ito S, Okuda-Ashitaka E, Minami T. Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 2001; 41: 299–332.PubMedCrossRef
3.
Taiwo YO, Levine JD. Prostaglandins inhibit endogenous pain control mechanisms by blocking transmission at spinal noradrenergic synapses. J Neurosci 1998; 8: 1346–9
4.
Uda R, Horiguchi S, Ito S, et al. Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, F2 to conscious mice. Brain Res 1990; 510: 26–32PubMedCrossRef
5.
Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 1992; 257: 1276–9PubMedCrossRef
6.
Minami T, Nishihara I, Uda R, et al. Characterization of EP-receptor subtypes involved in allodynia induced by intrathecal administration of prostaglandin E2. Br J Pharmacol 1994; 112: 735–40PubMedCrossRef
7.
Minami T, Uda R, Horiguchi S. Allodynia evoked by intrathecal administration of prostaglandin E2. Pain 1994; 57: 217–23PubMedCrossRef
8.
Vanegas H, Schaible H-G. Prostaglandins and cyclooxygenases in the spinal cord. Prog Neurobiol 2001; 64: 327–63PubMedCrossRef
9.
10.
Kawabata A, Umeda N, Takagi H. L-Arginine exerts a dual role in nociceptive processing in the brain: involvement of the kyotorphin-Met-enkephalin pathway and NO-cyclic GMP pathway. Br J Pharmacol 1993; 109: 73–9PubMedCrossRef
11.
Malmberg AB, Yaksh TL. Spinal nitric oxide synthesis inhibition blocks NMDA-induced thermal hyperalgesia and produces antinociception in the formalin test in rats. Pain 1993; 54: 291–300PubMedCrossRef
12.
Wiertelak EP, Furness LE, Watkins LR, et al. Illness-induced hyperalgesia is mediated by a spinal NMDA-nitric oxide cascade. Brain Res 1994; 664: 9–16PubMedCrossRef
13.
Linden DR, Seybold VS. Spinal neurokinin receptors mediate thermal but not mechanical hyperalgesia via nitric oxide. Pain 2000; 80: 309–17CrossRef
14.
Hamalainen MM, Lovick TA. Involvement of nitric oxide and serotonin in modulation of antinociception and pressor response evoked by stimulation in the dorsolateral region of the periaqueductal gray matter in the rat. Neuroscience 1997; 80: 821–7PubMedCrossRef
15.
Aley KO, McCater G, Levine JO. Nitric oxide signaling in pain and nociceptor sensitization in the rat. J Neurosci 1998; 18: 7008–14PubMed
16.
Gao WC, Ojao JT. Nitric oxide contributes to both spinal nociceptive transmission and its descending inhibition in rats: an immunocytochemical study. Neurosci Lett 1998; 40: 143–6CrossRef
17.
Ferreira J, Santos AR, Calixtom JB. The role of systemic spinal and supraspinal L-arginine-nitric oxide-cGMP pathway in thermal hyperalgesia caused by intrathecal injection of glutamate in mice. Neuropharmacology 1999; 38: 835–42PubMedCrossRef
18.
19.
Dawson TM, Snyder SH. Gases as biological messengers: nitric oxide and carbon monoxide in the brain. J Neurosci 1994; 14: 5137–53
20.
Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995; 57: 683–706PubMedCrossRef
21.
Coderre TJ. The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in rat. Molec Biol 1993; 7: 229–46
22.
Coderre TJ, Yashpal K. Intracellular messengers contributing to persistent nociception and hyperalgesia induced by L-glutamate and substance P in the rat formalin pain model. Eur J Neurosci 1994; 6: 1328–34PubMedCrossRef
23.
Kitto KF, Haley JE, Wilcox GL. Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse. Neurosci Lett 1992; 148: 1–5PubMedCrossRef
24.
Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391: 281–5PubMedCrossRef
25.
McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9–43PubMedCrossRef
26.
Ferreira SH. The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs 1993; 46: 1–9PubMedCrossRef
27.
Kaube H, Hoskin HL, Goadsby PJ. Intravenous acetylsalicylic acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal cord in the cat. Headache 1993; 33: 541–4PubMedCrossRef
28.
Sandrini M, Vitale G, Pini LA. Central antinociceptive activity of acetylsalicylic acid is modulated by brain serotonin receptor subtypes. Pharmacology 2002; 65: 193–7PubMedCrossRef
29.
Cashman JN. The mechanisms of action of NSAIDs in analgesia. Drugs 1996; 52 Suppl. 5: 13–23PubMedCrossRef
30.
O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993; 330: 156–60PubMedCrossRef
31.
Davis R, Brodgen RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54
32.
Tassorelli C, Joseph SA. Systemic nitroglycerin induces Fos immunoreactivity in brainstem and forebrain structures of the rat. Brain Res 1995; 682: 167–78PubMedCrossRef
33.
Tassorelli C, Joseph SA, Buzzi G, et al. The effect on the central nervous system of nitroglycerin —putative mechanisms and mediators. Prog Neurobiol 1999; 57: 606–24CrossRef
34.
Tassorelli C, Joseph SA, Nappi G. Neurochemical mechanisms of nitroglycerin-induced neuronal activation. Neuropharmacology 1997; 10: 1417–24CrossRef
35.
Tassorelli C, Greco R, Morocutti A, et al. Nitric oxide-induced neuronal activation in the central nervous system as an animal model for migraine: mechanisms and mediators. Funct Neurol 2001; 16 Suppl 4: 69–76PubMed
36.
Jones MG, Lever I, Bingham S, et al. Nitric oxide potentiates response of trigeminal neurones to dural or facial stimulation in the rat. Cephalalgia 2001; 21: 643–55PubMedCrossRef
37.
Reuter U, Chiarugi A, Bolay H, et al. Nuclear factor-kappaB as a molecular target for migraine therapy. Ann Neurol 2002; 51: 507–16PubMedCrossRef
38.
Tassorelli C, Greco R, Wang D, et al. Nitroglycerin induces hyperalgesia in rats — a time-course study. Eur J Pharmacol 2003; 464: 159–62PubMedCrossRef
39.
D'Armour FE, Smith DC. A method for determining loss of pain sensation. J Pharmacol Exp Ther 1980; 72: 74–9
40.
Tjolsen A, Berge OG, Hunskaar S, et al. The formalin test: an evaluation of the method. Pain 1992; 51: 5–17PubMedCrossRef
41.
Hao S, Takahata O, Iwasaki H. Intrathecal endorphin-1 produces antinociceptive activities modulated by alpha 2-adrenoceptors in the rat tail flick, tail pressure and formalin tests. Life Sci 2000; 66: 195–204CrossRef
42.
Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature 1983; 306: 686–8PubMedCrossRef
43.
Sengupta S, Velpandian T, Sapra P, et al. Comparative analgesic efficacy of nimesulide and diclofenac gels after topical application on the skin. Skin Pharmacol Appl Skin Physiol 1998; 11: 273–8PubMedCrossRef
44.
Gupta SK, Bansal P, Bhardwaj RK, et al. Comparative antinociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination. Pharmacol Res 2000; 41: 657–62PubMedCrossRef
45.
Matsumoto H, Naraba H, Ueno A, et al. Inhibition of cyclooxygenase-2 causes an enhancement of writhing response in mice. Eur J Pharmacol 1998; 352: 47–52PubMedCrossRef
46.
Bianchi M, Broggini M. Anti-hyperalgesic effects of nimesulide: studies in rats and humans. Int J Clin Pract 2002; 128 Suppl. 1: 11–9
47.
Islas-Cadena M, Banuelos P, Granados-Soto V. Evidence for the participation of the nitric oxide-cyclic GMP pathway in the antinociceptive effect of nimesulide. J Pharmacol Toxicol Metab 1999; 42: 87–92CrossRef
48.
Torfgard K, Ahnler J, Axelsson KL, et al. Tissue distribution of glyceryl trinitrate and the effect on cGMP levels in rat. Pharmacol Toxicol 1989; 64: 369–72PubMedCrossRef
49.
Mashimo T, Pak M, Choe H, et al. Effects of vasodilators guanethidine, nicardipine, nitroglycerin, and prostaglandin E1 on primary afferent nociceptors in humans. J Clin Pharmacol 1997; 37: 330–5PubMed
50.
Sandrini G, Tassorelli C, Proietti Cecchini A, et al. Effects of nimesulide on nitric oxide-induced hyperalgesia in humans — a neurophysiological study. Eur J Pharmacol 2002; 450: 259–62PubMedCrossRef
51.
Taniguchi Y, Yokoyama K, Inui K, et al. Inhibition of brain cyclooxygenase-2 activity and the antipyretic action of nimesulide. Eur J Pharmacol 1997; 330: 221–9PubMedCrossRef
52.
Taniguchi Y, Ikesue A, Yokoyama K, et al. Selective inhibition by nimesulide, a novel non-steroidal anti-inflammatory drug, of prostaglandin endoperoxidase synthase-2 activity in vitro. Pharmacol Sci 1995; 1: 173–5
53.
Vago T, Bevilacqua M, Norbiato G. Effect of nimesulide action time dependence on selectivity towards prostaglandin G/H synthase/cyclooxygenase activity. Arzneimittelforschung 1995; 45: 1096–8PubMed
54.
Beiche F, Geisslinger G, Goppelt-Struebe M. Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis. Inflamm Res 1988; 47: 482–7CrossRef
55.
Maihofner C, Tegeder I, Euchenhofer C, et al. Localization and regulation of cyclo-oxygenase-1 and -2 and neuronal nitric oxide synthase in mouse spinal cord. Neuroscience 2000; 101: 1093–108PubMedCrossRef
56.
Tegeder I, Niederberger E, Vetter G, et al. Effects of selective COX-1 and -2 inhibition on formalin-evoked nociceptive behavior and prostaglandin E2 release in the spinal cord. J Neurochem 2001; 79: 777–86PubMedCrossRef
57.
Torres-Lopez JE, Ortiz M, Castaneda-Hernandez G, et al. Comparison of the antinociceptive effect of celecoxib, diclofenac and resveratrol in the formalin test. Life Sci 2002; 70: 1669–76PubMedCrossRef
58.
Euchenhofer C, Maihofner C, Brune K, et al. Differential effect of selective cyclooxygenase-2 (COX-2) inhibitor NS 398 and diclofenac on formalin-induced nociception in the rat. Neurosci Lett 1998; 248: 25–8PubMedCrossRef
59.
Mazario J, Gaitan G, Herrero JF. Cyclooxygenase-1 vs. cyclooxygenase-2 inhibitors in the induction of antinociception in rodent withdrawal reflexes. Neurpharmacology 2001; 40: 937–46CrossRef
60.
Yaksh TL, Dirig DM, Conway CM, et al. The acute antihyperalgesic action of nonsteroidal, anti-inflammatory drugs and release of spinal prostaglandin E2 is mediated by the inhibition of constitutive spinal cyclooxygenase-2 (COX-2) but not COX-1. J Neurosci 2001; 21: 5847–53PubMed
61.
Yamamoto T, Nozaki-Taguchi N. The role of cyclooxygenase-1 and -2 in the rat formalin test. Anesth Analg 2002; 94: 962–7PubMedCrossRef
62.
Coderre TJ, Katz J, Vaccarino AL, et al. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52: 259–85PubMedCrossRef
63.
Sasaki M, Tohda C, Kuraishi Y. Region-specific increase in glutamate release from dorsal horn of rats with adjuvant inflammation. Neuroreport 1998; 9: 3219–22PubMedCrossRef
64.
Sluka KA, Willis WD. Increased spinal release of excitatory amino acids following intradermal injection of capsaicin is reduced by a protein kinase G inhibitor. Brain Res 1998; 798: 281–6PubMedCrossRef
65.
DeGroot J, Zhow S, Carlton SM. Peripheral glutamate release in the hind paw following low and high intensity sciatic stimulation. Neuroreport 2000; 14: 497–502CrossRef
66.
Lawand NB, McNearney T, Westlund KN. Amino acid release into the knee joint: key role in nociception and inflammation. Pain 2000; 86: 69–74PubMedCrossRef
67.
Ferreira SH, Lorenzetti BB. Intrathecal administration of prostaglandin E2 causes sensitization of the primary afferent neuron via the spinal release of glutamate. Inflamm Res 1996; 45: 499–502PubMedCrossRef
68.
Kawamata T, Omote K. Activation of spinal N-methyl-D-aspartate receptor stimulates a nitric oxide/cyclic guanosine 3,5-monophosphate/glutamate release cascade in nociceptive signaling. Anesthesiology 1999; 91: 1415–24PubMedCrossRef
69.
Dickenson AH. A cure for wind-up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci 1990; 11: 307–9PubMedCrossRef
70.
Minami T, Nishihara I, Uda R, et al. Involvement of glutamate receptors in allodynia induced by prostaglandin E2 and F2 alpha injected into conscious mice. Pain 1994; 57: 225–31PubMedCrossRef
Metadaten
Titel
Central Components of the Analgesic/ Antihyperalgesic Effect of Nimesulide: Studies in Animal Models of Pain and Hyperalgesia
verfasst von
Dr Cristina Tassorelli
Rosaria Greco
Giorgio Sandrini
Giuseppe Nappi
Publikationsdatum
01.11.2003
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe Sonderheft 1/2003
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200363001-00003